Cargando…
Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
OBJECTIVE: It is unknown whether there are differences in efficacy and safety between quetiapine extended‐release, 300 mg/d (QUEXR300), and olanzapine, 5‐20 mg/d (OLA), for Japanese patients with bipolar depression. METHODS: We conducted a Bayesian analysis of data from phase 3 studies in Japan of Q...
Autores principales: | Kishi, Taro, Ikuta, Toshikazu, Matsuda, Yuki, Iwata, Nakao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292317/ https://www.ncbi.nlm.nih.gov/pubmed/31283865 http://dx.doi.org/10.1002/npr2.12070 |
Ejemplares similares
-
Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020) -
A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
por: Kishi, Taro, et al.
Publicado: (2023) -
Body composition in Japanese patients with psychiatric disorders: A cross‐sectional study
por: Kishi, Taro, et al.
Publicado: (2021) -
Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta‐analysis of double‐blind, randomized, placebo‐controlled trials with an enrichment design
por: Oya, Kazuto, et al.
Publicado: (2019) -
Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020)